Docoh
Loading...

ALT Altimmune

GRANT
Utility
Rapid and prolonged immunologic-therapeutic
12 Oct 21
The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings.
De-chu C Tang
Filed: 28 Mar 21
APP
Utility
Coronavirus Immunogenic Compositions and Uses Thereof
26 Aug 21
Provided in the present disclosure are immunogenic compounds, pharmaceutical formulations thereof and their use for inducing a protective immune response against 2019 novel coronavirus (SARS-CoV-2) infection and variants in a mammal.
Bertrand Victor Gilbert Georges, M. Scot Roberts
Filed: 12 Feb 21
APP
Utility
Coronavirus Immunogenic Compositions and Uses Thereof
26 Aug 21
Provided in the present disclosure are immunogenic compounds, pharmaceutical formulations thereof and their use for inducing a protective immune response against 2019 novel coronavirus (SARS-CoV-2) infection and variants in a mammal.
Bertrand Victor Gilbert Georges, M. Scot Roberts
Filed: 12 Feb 21
APP
Utility
Rapid and Prolonged Immunologic-therapeutic
26 Aug 21
The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings.
De-chu C Tang
Filed: 28 Mar 21
APP
Utility
T-cell Inducing Vaccine Composition Combination and Uses Thereof
5 Aug 21
Provided herein are vaccine combinations and methods for enhancing an antigen specific T cell induced response in a subject in need thereof.
Bertrand Georges, Scot Roberts
Filed: 4 Apr 19
GRANT
Utility
Rapid and prolonged immunologic therapeutic
22 Jun 21
The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings.
De-Chu C Tang
Filed: 11 Jul 20
GRANT
Utility
Rapid and prolonged immunogic therapeutic
22 Jun 21
The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings.
De-Chu C Tang
Filed: 12 Jul 20
APP
Utility
Fluorocarbon-Linked Peptide Formulation
11 Feb 21
The invention provides an aqueous acidic formulation suitable for use as in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation, which aqueous formulation comprises a first fluorocarbon-linked peptide, wherein: the peptide linked to the fluorocarbon is at least 20 amino acid residues long, comprises at least 50% hydrophobic amino acid residues and has an isoelectric point greater than or equal to 7; and the fluorocarbon-linked peptide is present in micelles.
Carlton Bradley Brown, Bertrand Victor Gilbert Georges, Jean Francois Thaburet
Filed: 23 Jun 20
GRANT
Utility
Immunogenic compound
30 Nov 20
The present application relates to an immunostimulatory compound comprising an immunostimulant portion and a peptide portion.
Bertrand Georges
Filed: 6 Oct 19
APP
Utility
Rapid and Prolonged Immunogic Therapeutic
28 Oct 20
The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings.
De-Chu C Tang
Filed: 10 Jul 20
APP
Utility
Rapid and Prolonged Immunogic Therapeutic
28 Oct 20
The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings.
De-Chu C Tang
Filed: 11 Jul 20
APP
Utility
Immunizations of Avians by Administration of Non-replicating Vectored Vaccines
28 Oct 20
The present invention relates generally to the fields of immunology and vaccine technology.
De-Chu C Tang, Kent VAN KAMPEN, Haroldo Toro
Filed: 9 Jul 20
APP
Utility
Broad and Long-lasting Influenza Vaccine
7 Oct 20
Provided herein are monovalent pharmaceutical compositions (vaccine compositions) and methods for inducing a multi-arm (mucosal, humoral and cell-mediated) immune response and extended seroprotection of at least 12 months post vaccination against influenza virus.
Scot Roberts, Sybil Tasker
Filed: 5 Apr 20
APP
Utility
Locally Acting Toll-like Receptor 7 (TLR7) And/or TLR8 Agonist Immunotherapy Compounds and Their Uses
7 Oct 20
Provided in the present disclosure are immunotherapy compounds, pharmaceutical compositions thereof and their use, wherein the immunotherapy compounds, upon local administration, form depots inducing cell mediated immune response while mitigating a systemic proinflammatory immune response.
Bertrand Georges, Scot Roberts, Isabelle Peguillet
Filed: 31 Mar 20
GRANT
Utility
Immunization of avians by administration of non-replicating vectored vaccines
17 Aug 20
The present invention relates generally to the fields of immunology and vaccine technology.
De-Chu C. Tang, Kent R. Van Kampen, Haroldo Toro
Filed: 27 Nov 17
GRANT
Utility
Fluorocarbon-linked peptide formulation
3 Aug 20
The invention provides an aqueous acidic formulation suitable for use as in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation, which aqueous formulation comprises a first fluorocarbon-linked peptide, wherein: the peptide linked to the fluorocarbon is at least 20 amino acid residues long, comprises at least 50% hydrophobic amino acid residues and has an isoelectric point greater than or equal to 7; and the fluorocarbon-linked peptide is present in micelles.
Carlton Bradley Brown, Bertrand Victor Gilbert Georges, Jean Francois Thaburet
Filed: 22 Jul 15
  • 1
Patents are sorted by USPTO publication date, most recent first